Director, Analytical Development (Ophthalmic Drug Delivery)

Run my Accounts AG; Irvine (CA); On-site; USD 225,000 - 250,000; Full time

Benefits offered by this job

Stock options

Annual bonus

Health, dental, vision insurance

Generous paid time off

Job summary

SpyGlass Pharma seeks a Director of Analytical Development to lead late-stage analytical activities for the lead program advancing through Phase 3 towards NDA submission.

The role provides technical leadership for method development, qualification, validation, stability, and tech transfer, coordinating with cross-functional teams to ensure robust analytical support for regulatory submissions and commercial readiness.

Qualifications

• PhD or equivalent in analytical chemistry, organic chemistry, biochemistry, chemical engineering, pharmaceutical sciences, or related field with 10+ years in small molecule development.
• Expertise in chromatography, spectroscopy, mass spectrometry, and physicochemical characterization.
• Strong knowledge of ICH, USP/EP, and cGMP requirements.
• Proven ability to lead and mentor a team in a collaborative, high-performing environment.
• Excellent communication skills across stakeholders.

Responsibilities

• Define and execute analytical development strategies across the pipeline.
• Lead and manage scientists in developing, validating, and transferring analytical methods.
• Collaborate with cross-functional teams to support product development programs.
• Design and execute analytical development plans through commercialization.
• Oversee stability programs and establish retest periods and shelf life.
• Direct multiple internal and CRO resources to meet objectives.
• Review analytical protocols, reports, and regulatory submissions for accuracy and compliance.
• Foster a culture of continuous improvement and collaboration within the team.

Skills

Leadership

Communication

Mentoring

Education

PhD or equivalent in analytical/related field

Job description

SpyGlass Pharma seeks a Director of Analytical Development to lead late-stage analytical activities for the lead program advancing through Phase 3 towards NDA submission.

The role provides technical leadership for method development, qualification, validation, stability, and tech transfer, coordinating with cross-functional teams to ensure robust analytical support for regulatory submissions and commercial readiness.